In a single-arm clinical study, tazemetostat, an oral EZH2 inhibitor, demonstrated significant therapeutic efficacy and safety in follicular lymphoma treatment, particularly in the EZH2 wild-type cohort (Morschhauser et al., 2020). This evidence concerns the gene EZH2 and follicular lymphoma.